S F Abdel Aal | PubMed Health

PubMed1991

Hydantoin immunosuppression clinical study.

A study was conducted on 51 epileptic patients divided into two groups. Group 1: 20 patients without anticonvulsant treatment for at least two years, and group II: 31 patients receiving phenytoin in a dose of 300 mg/24 hr for at least 4 months. A group of normal and blood donor subjects were used as control. The serum concentrations of IgA and IgM were significantly decreased in the phenytoin treated patients in comparison with control. Non-treated epileptics showed a significant decrease of IgA level in comparison with control. It was suggested that phenytoin treatment suppresses the normal function of the humoral immune response and that epilepsy may be a contributing factor.

Adolescent↗

PubMed1989

Liver injury associated with N-acetylcysteine administration.

90 adult male albino rats, were divided into two groups each comprising 45 rats out of which 15 were used as controls. N-acetylcysteine was given orally in a doses of 300 and 600 mg/Kg body weight respectively for three weeks. At the end of each week 10 rats from each experimental group as well as 5 rats from control animals were sacrificed and biochemical and pathological studies for hepatic functions and structure were performed. NAC in the high dose group induced significant changes in the liver function tests suggestive of liver dysfunction and damage. Histopathological studies revealed cell ballooning portal dilatation with round cell infiltration, portal tract fibrosis and proliferations. It was concluded that NAC in small dose is safe and can be used, while in large dose it has a hepatotoxic potential.

Acetylcysteine↗